Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.
GEN - Genetic Engineering and Biotechnology News1d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Medscape13y
Acute Liver Failure in Neonates, Infants and Children
Acute liver failure (ALF) is a rare but devastating syndrome. ALF in children differs from that observed in adults in both the etiologic spectrum and the clinical picture. Specific therapy to ...
European Medical Journal10d
A Promising Biomarker for Predicting Acute-on-Chronic Liver Failure: ECR 2025
A study presented at ECR 2025 has identified the Functional Liver Imaging Score as a valuable prognostic biomarker for ...
Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies
Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
Medscape2mon
Acute Liver Failure in Neonates, Infants and Children
Pediatric acute liver failure. Data taken from [10,14]. Hereditary tyrosinemia Nitisinone (NTBC or 2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione) 1 mg/kg/day orally in two doses ...